#ECTRIMS2021 – Analysis Finds Soliris May Be Better at Reducing Relapses
Note: This story was updated Nov. 2, 2021, to note that Soliris is taken every two weeks, rather than weekly. Soliris (eculizumab) is more effective than Enspryng (satralizumab) and Uplizna (inebilizumab) at lowering the risk of relapse in adults with neuromyelitis optica spectrum disorder (NMOSD) who are…